Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])

BACKGROUND AND PURPOSE—: We conducted a randomized, open-label, phase 1/2a, dose-escalation study of intraventricular sustained-release nimodipine (EG-1962) to determine safety, tolerability, pharmacokinetics, and clinical effects in aneurysmal subarachnoid hemorrhage. METHODS—: Subjects with aneury...

Descripción completa

Detalles Bibliográficos
Autores principales: Hänggi, Daniel, Etminan, Nima, Aldrich, Francois, Steiger, Hans Jakob, Mayer, Stephan A., Diringer, Michael N., Hoh, Brian L., Mocco, J, Faleck, Herbert J., Macdonald, R. Loch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5176000/
https://www.ncbi.nlm.nih.gov/pubmed/27932607
http://dx.doi.org/10.1161/STROKEAHA.116.014250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5176000/
https://www.ncbi.nlm.nih.gov/pubmed/27932607
http://dx.doi.org/10.1161/STROKEAHA.116.014250

Ejemplares similares